There are many reasons why parties to a lawsuit decide to settle.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.
90 percent of those undergoing FMT had one-month cure; 4 percent had recurrence within six months
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
The aim of the study was to use real-world data to compare the risk of cardiac events in new users of azithromycin vs amoxicillin.
The observational study aimed to determine the association between fluoroquinolone use and the risk of aortic aneurysm or aortic dissection while taking into account potential confounding.
The new doses of Vanco Ready include 150mL, 250mL, and 350mL premixed bags containing 750mg, 1.25g, and 1.75g of vancomycin, respectively.